Professor David Burden

Honorary Professor (School of Infection & Immunity)

email: David.Burden@glasgow.ac.uk

Department of Dermatology, Western Infirmary

Import to contacts

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2009 | 2007 | 2005

Number of items: 91.

2024

Hernandez-Cordero, A. et al. (2024) A genome-wide meta-analysis of palmoplantar pustulosis implicates Th2 responses and cigarette smoking in disease pathogenesis. Journal of Allergy and Clinical Immunology, 154(3), 657-665.e9. (doi: 10.1016/j.jaci.2024.05.015) (PMID:38815935)

Choon, S. E. et al. (2024) International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council. JAMA Dermatology, 160(7), pp. 758-768. (doi: 10.1001/jamadermatol.2024.0915) (PMID:38691347)

Morita, A. et al. (2024) Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil ™ 2 study. Future Rare Diseases, 4(1), FRD57. (doi: 10.2217/frd-2023-0023)

Burden, A. D. (2024) Response to: letter to editor regarding “Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study”. Dermatology and Therapy, 14(4), pp. 1067-1069. (doi: 10.1007/s13555-024-01138-8) (PMID:38578385) (PMCID:PMC11052932)

Barker, J. N., Becher, G., Burden, D. A., Pink, A. E., Zacharioudaki, M. and Warren, R. B. (2024) Clinical course, treatment and management of generalised pustular psoriasis from a United Kingdom extension of a global Delphi panel. Skin Health and Disease, 4(3), e359. (doi: 10.1002/ski2.359) (PMID:38846692) (PMCID:PMC11150733)

Burden, A. D. et al. (2024) Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy–Fatigue and pain‐Visual Analogue Scale in patients with generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, (doi: 10.1111/jdv.19830) (PMID:38334243) (Early Online Publication)

2023

Morita, A. et al. (2023) Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet, 402(10412), pp. 1541-1551. (doi: 10.1016/S0140-6736(23)01378-8) (PMID:37738999)

Smith, C. H. et al. (2023) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023 – a pragmatic update. British Journal of Dermatology, 190(2), pp. 270-272. (doi: 10.1093/bjd/ljad347) (PMID:37740557)

Burden, A. D., Bissonnette, R., Navarini, A. A., Murakami, M., Morita, A., Haeufel, T., Ye, B., Baehner, F. and Terui, T. (2023) Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study. Dermatology and Therapy, 13(10), pp. 2279-2297. (doi: 10.1007/s13555-023-01002-1) (PMID:37731086) (PMCID:PMC10539230)

Burden, A. D. et al. (2023) The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. British Journal of Dermatology, 189(1), pp. 138-140. (doi: 10.1093/bjd/ljad071) (PMID:37075220)

Burden, A. D., Bissonnette, R., Lebwohl, M. G., Gloede, T., Anatchkova, M., Budhiarso, I., Hu, N., Thoma, C., Skalicky, A. M. and Bachelez, H. (2023) Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). Journal of the European Academy of Dermatology and Venereology, 37(7), pp. 1327-1335. (doi: 10.1111/jdv.18999) (PMID:36854864)

Burden, A.D., Okubo, Y., Zheng, M., Thaçi, D., van de Kerkhof, P., Hu, N., Quaresma, M., Thoma, C. and Choon, S. E. (2023) Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Experimental Dermatology, 32(8), pp. 1279-1283. (doi: 10.1111/exd.14824) (PMID:37140190)

Burden, A. D. (2023) Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Review of Clinical Immunology, 19(5), pp. 473-481. (doi: 10.1080/1744666X.2023.2195165) (PMID:36960829)

Niaouris, A. et al. (2023) Damaging alleles affecting multiple CARD14 domains are associated with palmoplantar pustulosis. Journal of Investigative Dermatology, 143(3), 504-508.e5. (doi: 10.1016/j.jid.2022.07.031) (PMID:36174714)

Tsakok, T. et al. (2023) Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove. JCI Insight, 8(4), e156643. (doi: 10.1172/jci.insight.156643) (PMID:36810251) (PMCID:PMC9977494)

Morita, A. et al. (2023) Design of Effisayil™ 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatology and Therapy, 13(1), pp. 347-359. (doi: 10.1007/s13555-022-00835-6) (PMID:36333618) (PMCID:PMC9823166)

2022

Bachelez, H., Barker, J., Burden, A. D., Navarini, A. A. and Krueger, J. G. (2022) Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Review of Clinical Immunology, 18(10), pp. 1033-1047. (doi: 10.1080/1744666X.2022.2116003) (PMID:36062811)

McCluskey, D. et al. (2022) Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology, 150(4), pp. 882-893. (doi: 10.1016/j.jaci.2022.04.027) (PMID:35568077)

Finlay, A. Y., Barker, J. N., Burden, A. D., Griffiths, C. E. M., Kirby, B., Goodman, M. L., Neill, C. and Warren, R. B. (2022) Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE). JEADV Clinical Practice, 1(3), pp. 207-218. (doi: 10.1002/jvc2.42)

Burden, A. D., Mrowietz, U., Skalicky, A. M., Rentz, A. M., Esser, D., Gloede, T., Thoma, C. and Menter, A. (2022) Symptom experience and content validity of the Psoriasis Symptom Scale (PSS) in patients with generalized pustular psoriasis (GPP). Dermatology and Therapy, 12(6), pp. 1367-1381. (doi: 10.1007/s13555-022-00736-8) (PMID:35590037) (PMCID:PMC9209619)

Choon, S. E. et al. (2022) Spesolimab treatment for people with flares of generalized pustular psoriasis: a plain language summary of the Effisayil™ 1 study. Future Rare Diseases, 2(2), FRD25. (doi: 10.2217/frd-2022-0002)

Cro, S. et al. (2022) Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). British Journal of Dermatology, 186(2), pp. 245-256. (doi: 10.1111/bjd.20653) (PMID:34411292)

Burden, A. D., Choon, S. E., Gottlieb, A. B., Navarini, A. A. and Warren, R. B. (2022) Clinical disease measures in generalized pustular psoriasis. American Journal of Clinical Dermatology, 23(Suppl1), pp. 39-50. (doi: 10.1007/s40257-021-00653-0) (PMID:35061231) (PMCID:PMC8801406)

2021

Mason, K. J. et al. (2021) Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 35(8), e496-e498. (doi: 10.1111/jdv.17282) (PMID:33866626)

Mason, K. J. et al. (2021) Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. Journal of the European Academy of Dermatology and Venereology, 35(8), e498-e501. (doi: 10.1111/jdv.17230) (PMID:33725378)

Becher, G. and Burden, A.D. (2021) Psoriasis, COVID-19 and shielding. British Journal of Dermatology, 185(1), pp. 7-8. (doi: 10.1111/bjd.20055) (PMID:33951179) (PMCID:PMC8239873)

O’Shaughnessy, E. M., Duffy, W., Garcia-Vega, L., Hussey, K., Burden, A. D., Zamiri, M. and Martin, P. E. (2021) Dysregulation of connexin expression plays a pivotal role in psoriasis. International Journal of Molecular Sciences, 22(11), 6060. (doi: 10.3390/ijms22116060) (PMID:34199748) (PMCID:PMC8200029)

Mrowietz, U. et al. (2021) Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatology and Therapy, 11, pp. 571-585. (doi: 10.1007/s13555-021-00504-0) (PMID:33661508) (PMCID:PMC8019016)

Choon, S. E. et al. (2021) Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open, 11(3), e043666. (doi: 10.1136/bmjopen-2020-043666) (PMID:33785490) (PMCID:PMC8011793)

Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R. and Jagiello, P. (2021) Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study. Journal of the American Academy of Dermatology, 84(2), pp. 552-554. (doi: 10.1016/j.jaad.2020.06.038) (PMID:32565211)

Smith, C. H. et al. (2021) Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis-correction. Journal of Investigative Dermatology, 141(1), pp. 177-181. (doi: 10.1016/j.jid.2020.02.048) (PMID:33342507)

Bachelez, H. et al. (2021) Trial of spesolimab for generalized pustular psoriasis. New England Journal of Medicine, 385(26), pp. 2431-2440. (doi: 10.1056/NEJMoa2111563) (PMID:34936739)

Jones, G. T., Macfarlane, G. J., Forrest Keenan, K., McNamee, P., Neilson, A. R., Siebert, S. , Burden, A. D., Kay, L. and Helliwell, P. S. (2021) The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. BMC Rheumatology, 5, 19. (doi: 10.1186/s41927-021-00189-0) (PMID:33993880) (PMCID:PMC8126428)

2020

Loeff, F. C. et al. (2020) Clinical impact of antibodies against ustekinumab in psoriasis: An observational, cross-sectional, multicenter study. Journal of Investigative Dermatology, 140(11), pp. 2129-2137. (doi: 10.1016/j.jid.2020.03.957) (PMID:32283057)

Mahil, S.K. et al. (2020) Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis. British Journal of Dermatology, 183(4), pp. 638-649. (doi: 10.1111/bjd.19325) (PMID:32562551)

Smith, C.H. et al. (2020) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. British Journal of Dermatology, 183(4), pp. 628-637. (doi: 10.1111/bjd.19039) (PMID:32189327)

Vergnano, M. et al. (2020) Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. American Journal of Human Genetics, 107(3), pp. 539-543. 32758448. (doi: 10.1016/j.ajhg.2020.06.020) (PMID:PMC7477255)

Warren, R.B., Barker, J.N.W.B., Finlay, A.Y., Burden, A.D., Kirby, B., Armendariz, Y., Williams, R., Hatchard, C., Khare, S. and Griffiths, C.E.M. (2020) Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE). British Journal of Dermatology, 183(1), pp. 60-70. (doi: 10.1111/bjd.18623) (PMID:31628677)

Mahil, S.K. et al. (2020) Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). British Journal of Dermatology, 182(5), pp. 1158-1166. (doi: 10.1111/bjd.18333) (PMID:31286471) (PMCID:PMC7317460)

Catapano, M. et al. (2020) IL-36 promotes systemic IFN-I responses in severe forms of psoriasis. Journal of Investigative Dermatology, 140(4), 816-826.e3. (doi: 10.1016/j.jid.2019.08.444) (PMID:31539532) (PMCID:PMC7097848)

Rungapiromnan, W. et al. (2020) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), pp. 769-778. (doi: 10.1111/jdv.16018) (PMID:31633837)

Cro, S. et al. (2020) A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 21, 158. (doi: 10.1186/s13063-020-4103-z) (PMID:32041649) (PMCID:PMC7011285)

Benzian-Olsson, N. et al. (2020) Association of clinical and demographic factors with the severity of palmoplantar pustulosis. JAMA Dermatology, 156(11), pp. 1216-1222. (doi: 10.1001/jamadermatol.2020.3275) (PMID:32936291) (PMCID:PMC7495329)

Pan, S. et al. (2020) Using real‐world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic‐pharmacodynamic study. Clinical and Translational Science, 13(2), pp. 400-409. (doi: 10.1111/cts.12725) (PMID:31995663) (PMCID:PMC7070790)

2019

Yiu, Z.Z.N., Mason, K.J., Barker, J.N.W.N., Hampton, P.J., McElhone, K., Smith, C.H., Warren, R.B., Griffiths, C.E.M., Lunt, M. and Burden, A.D. (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis. British Journal of Dermatology, 181(6), pp. 1265-1271. (doi: 10.1111/bjd.17849) (PMID:30822358)

Dand, N. et al. (2019) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), pp. 2120-2130. (doi: 10.1016/j.jaci.2018.11.038) (PMID:30578879)

Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R. and Chaouche-Teyara, K. (2019) Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. Journal of the American Academy of Dermatology, 80(5), pp. 1344-1352. (doi: 10.1016/j.jaad.2019.01.066) (PMID:30716404)

Warren, R.B. et al. (2019) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), pp. 1069-1076. (doi: 10.1111/bjd.16776) (PMID:30155885) (PMCID:PMC6519065)

Bachelez, H. et al. (2019) Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. New England Journal of Medicine, 380(10), pp. 981-983. (doi: 10.1056/NEJMc1811317) (PMID:30855749)

Twelves, S. et al. (2019) Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 143(3), pp. 1021-1026. (doi: 10.1016/j.jaci.2018.06.038) (PMID:30036598) (PMCID:PMC6403101)

Wilkinson, N. et al. (2019) Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. Journal of Investigative Dermatology, 139(1), pp. 115-123. (doi: 10.1016/j.jid.2018.07.028) (PMID:30130616) (PMCID:PMC6300405)

Tsakok, T. et al. (2019) Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatology, 155(11), pp. 1235-1243. (doi: 10.1001/jamadermatol.2019.1783)

2018

Petridis, C. et al. (2018) Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nature Communications, 9, 5075. (doi: 10.1038/s41467-018-07459-5) (PMID:30542056) (PMCID:PMC6290788)

Shams, K., Kurowska-Stolarska, M. , Schütte, F., Burden, A. D., McKimmie, C. S. and Graham, G. J. (2018) MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2. Journal of Biological Chemistry, 293(8), pp. 3003-3012. (doi: 10.1074/jbc.M117.809780) (PMID:29279330) (PMCID:PMC5827444)

Mason, K. J., Barker, J. N. W. N., Smith, C. H., Hampton, P. J., Lunt, M., McElhone, K., Warren, R. B., Yiu, Z. Z. N., Griffiths, C. E. M. and Burden, A. D. (2018) Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatology, 154(5), pp. 581-588. (doi: 10.1001/jamadermatol.2018.0183) (PMID:29590279) (PMCID:PMC5876819)

Pottinger, E., Woolf, R.T., Exton, L.S., Burden, A.D., Nelson‐Piercy, C. and Smith, C.H. (2018) Exposure to biological therapies during conception and pregnancy: a systematic review. British Journal of Dermatology, 178(1), pp. 95-102. (doi: 10.1111/bjd.15802) (PMID:28718898)

2017

Dand, N. et al. (2017) Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 26(21), pp. 4301-4313. (doi: 10.1093/hmg/ddx328) (PMID:28973304)

Navarini, A. A., Burden, A. D., Capon, F., Mrowietz, U., Puig, L., Köks, S., Kingo, K., Smith, C. and Barker, J. N. (2017) European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(11), pp. 1792-1799. (doi: 10.1111/jdv.14386) (PMID:28585342)

Burden, A.D. (2017) Etanercept or infliximab for psoriasis? An independent randomized clinical trial. British Journal of Dermatology, 176(3), p. 565. (doi: 10.1111/bjd.15160) (PMID:28300301)

Graham, G. et al. (2017) Spread of psoriasiform inflammation to remote tissues is restricted by the atypical chemokine receptor ACKR2. Journal of Investigative Dermatology, 137(1), pp. 85-94. (doi: 10.1016/j.jid.2016.07.039) (PMID:27568525) (PMCID:PMC5176004)

Davison, N.J., Warren, R.B., Mason, K.J., McElhone, K., Kirby, B., Burden, A.D., Smith, C.H., Payne, K. and Griffiths, C.E.M. (2017) Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study. British Journal of Dermatology, 177(3), pp. 828-836. (doi: 10.1111/bjd.15551) (PMID:28386916)

Iskandar, I.Y.K., Ashcroft, D.M., Warren, R.B., Evans, I., McElhone, K., Owen, C.M., Burden, A.D., Smith, C.H., Reynolds, N.J. and Griffiths, C.E.M. (2017) Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 176(5), pp. 1297-1307. (doi: 10.1111/bjd.15027) (PMID:27589476)

Jabbar-Lopez, Z. K. et al. (2017) Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. Journal of Investigative Dermatology, 137(8), pp. 1646-1654. (doi: 10.1016/j.jid.2017.04.009) (PMID:28457908) (PMCID:PMC5519491)

Smith, C.H. et al. (2017) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177(3), pp. 628-636. (doi: 10.1111/bjd.15665) (PMID:28513835)

2016

Mahil, S. K. et al. (2016) AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. Journal of Investigative Dermatology, 136(11), pp. 2251-2259. (doi: 10.1016/j.jid.2016.06.618)

Yesudian, P. D., Leman, J., Balasubramaniam, P., Macfarlane, A. W., Al-Niaimi, F., Griffiths, C. E. M., Burden, A. D. and Warren, R. B. (2016) Effectiveness of subcutaneous methotrexate in chronic plaque psoriasis. Journal of Drugs in Dermatology, 15(3), pp. 345-349.

Krishnadas, R. et al. (2016) Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 51, pp. 29-38. (doi: 10.1016/j.bbi.2015.08.005) (PMID:26255693)

Yiu, Z. Z.N. et al. (2016) Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. Journal of Investigative Dermatology, 136(8), pp. 1584-1591. (doi: 10.1016/j.jid.2016.03.035) (PMID:27085754) (PMCID:PMC4946794)

2015

Griffiths, C. E. M., Barnes, M. R., Burden, A. D., Nestle, F. O., Reynolds, N. J., Smith, C. H., Warren, R. B. and Barker, J. N. W. N. (2015) Establishing an academic–industrial stratified medicine consortium: psoriasis stratification to optimize relevant therapy. Journal of Investigative Dermatology, 135(12), pp. 2903-2907. (doi: 10.1038/jid.2015.286) (PMID:26569580)

Warren, R. B. et al. (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). Journal of Investigative Dermatology, 135(11), pp. 2632-2640. (doi: 10.1038/jid.2015.208) (PMID:26053050)

Iskandar, I.Y.K. et al. (2015) Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 173(2), pp. 510-518. (doi: 10.1111/bjd.13908) (PMID:25989336)

Berki, D. M. et al. (2015) Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. Journal of Investigative Dermatology, 135(12), pp. 2964-2970. (doi: 10.1038/jid.2015.288) (PMID:26203641)

Hussain, S. et al. (2015) IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. Journal of Allergy and Clinical Immunology, 135(4), 1067-1070.e9. (doi: 10.1016/j.jaci.2014.09.043) (PMID:25458002)

2014

Coates, L. C. et al. (2014) Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care and Research, 66(9), pp. 1410-1416. (doi: 10.1002/acr.22284)

Setta-Kaffetzi, N. et al. (2014) AP1S3 mutations are associated with pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. American Journal of Human Genetics, 94(5), pp. 790-797. (doi: 10.1016/j.ajhg.2014.04.005)

Coates, L.C. et al. (2014) Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 170(4), pp. 995-996. (doi: 10.1111/bjd.12824)

Navarini, A. A. et al. (2014) Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. Nature Communications, 5, p. 4020. (doi: 10.1038/ncomms5020)

2012

Singh, M.D. et al. (2012) Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. American Journal of Pathology, 181(4), pp. 1158-1164. (doi: 10.1016/j.ajpath.2012.06.042) (PMID:22867710) (PMCID:PMC3532592)

Becher, G. and Burden, A.D. (2012) Understanding the variation in response to methotrexate. British Journal of Dermatology, 167(1), pp. 2-3. (doi: 10.1111/j.1365-2133.2012.11028.x)

Capon, F., Burden, A.D., Trembath, R.C. and Barker, J.N. (2012) Psoriasis and other complex trait dermatoses: from loci to functional pathways. Journal of Investigative Dermatology, 132(3), pp. 915-922. (doi: 10.1038/jid.2011.395)

Onoufriadis, A., Simpson, M.A., Burden, A.D., Barker, J.N., Trembath, R.C. and Capon, F. (2012) Identification of rare, disease-associated variants in the promoter region of the RNF114 psoriasis susceptibility gene. Journal of Investigative Dermatology, 132(4), pp. 1297-1299. (doi: 10.1038/jid.2011.431)

2011

Onoufriadis, A. et al. (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. American Journal of Human Genetics, 89(3), pp. 432-437. (doi: 10.1016/j.ajhg.2011.07.022)

Wylie, G., Makrygeorgou, A. and Burden, A.D. (2011) Buccal prochlorperazine causing perioral fixed drug eruption. Clinical and Experimental Dermatology, 36(6), pp. 672-673. (doi: 10.1111/j.1365-2230.2011.04020.x)

Burden, A.D. (2011) Drug survival rates for tumour necrosis factor-α antagonists in psoriasis. British Journal of Dermatology, 164(5), pp. 940-941. (doi: 10.1111/j.1365-2133.2011.10355.x)

Laws, P.M. et al. (2011) Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 166(1), pp. 189-195. (doi: 10.1111/j.1365-2133.2011.10638.x)

Tziotzios, C. and Burden, D. (2011) Swelling scars. QJM: An International Journal of Medicine, 104(5), pp. 445-446. (doi: 10.1093/qjmed/hcq040)

Wylie, G.R. and Burden, D. (2011) Renbok phenomenon between psoriasis and alopecia areata. Clinical and Experimental Dermatology, 36(7), pp. 816-817. (doi: 10.1111/j.1365-2230.2011.04097.x)

2009

Al-Niaimi, F., Jury, C., Burden, D. and Mealyea, M. (2009) Changing patterns of zoophilic fungal infections in the West of Scotland illustrated by two cases of tinea corporis from domestic rodents. Clinical and Experimental Dermatology, 34(8), pp. 925-926. (doi: 10.1111/j.1365-2230.2008.03101.x)

May, C., Burden, D., Palmer, M. and Leman, J. (2009) Peyronie's disease associated with methotrexate therapy. Clinical and Experimental Dermatology, 34(7), e467-e468.

2007

Zhao, Y. et al. (2007) Filaggrin null alleles are not associated with psoriasis. Journal of Investigative Dermatology, 127, pp. 1878-1882. (doi: 10.1038/sj.jid.5700817)

2005

Abecasis, G. et al. (2005) Fine mapping of the psoriasis susceptibility gene PSORS1: A reassessment of risk associated with a putative risk haplotype lacking HLA-Cw6. Journal of Investigative Dermatology, 124, pp. 921-930. (doi: 10.1111/j.0022-202X.2005.23729.x)

This list was generated on Mon Nov 18 23:17:10 2024 GMT.

Jump to: Articles